OOIR: Observatory of International Research

Papers

(The median citation count of Lupus Science & Medicine is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis	178
Mortality patterns of SLE and the associated risk factors in Korean patients: a nationwide cohort study	49
COVID-19 vaccination questionnaire in patients with systemic lupus erythematosus: an observational study	46
Scleroderma-like capillaroscopic pattern in SLE is not a sign of overlap syndrome in both adults and children	40
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE	40
One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria	39
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms	37
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up	32
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study	32
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children	29
Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study	27
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus	27
COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology	26
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases	26
Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS)	23
Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study	23
High-density lipoprotein cholesterol subfraction HDL2 is associated with improved endothelial function in systemic lupus erythematosus	22
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus	22
Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay andCrithidia luciliaeassay in a multiethnic racial cohort of patients with SLE	22
Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins	20
Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms	20
Comparing dermatologic patient-reported outcome measures in cutaneous lupus erythematosus	19
Genetic load in incomplete lupus erythematosus	19
Dialogue: Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS)	19
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field	19

Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus	19
Correction of omega-3 fatty acid deficiency and improvement in disease activity in patients with systemic lupus erythematosus treated with krill oil concentrate: a multicentre, randomised, double-blin	18
Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)	18
HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis	17
Prevalence of coeliac disease in patients with systemic lupus erythematosus: a systematic review and meta-analysis	17
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease	17
Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE	16
Activation-induced colocalisation of SCAMP5 with IFNα in human plasmacytoid dendritic cells	16
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort	16
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption	15
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol	15
Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE	15
Lupus pathogenesis and autoimmunity are exacerbated by high fat diet-induced obesity in MRL/lpr mice	15
Validating claims-based algorithms for a systemic lupus erythematosus diagnosis in Medicare data for informed use of the Lupus Index: a tool for geospatial research	14
Dialogue: Hydroxychloroquine pharmacokinetic (PK) and exposure response in pregnancies with systemic lupus erythematosus: the importance of adherence for neonatal outcome	13
Absence of renal remission portends poor long-term kidney outcome in lupus nephritis	13
Impact of disease activity patterns on health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE)	13
The Care-coordination Approach to Learning Lupus Self-Management: a patient navigator intervention for systemic lupus inpatients	13
Cutaneous lupus concerns from the patient perspective: a qualitative study	13
Altered structural and functional homotopic connectivity associated with cognitive changes in SLE	13
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes	13
Evaluation of primary aldosteronism testing in hypertensive patients with SLE in a tertiary hospital	12
Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study	12
Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus	12
Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study	12
Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis	12
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus	12
Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional study	12
Ras-MAPK pathway in patients with lupus nephritis	11
Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study	11
CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?	11
Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis	11
Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history	11
Breastfeeding in women with rheumatic diseases	11
Comparison of flares in 85 patients with SLE who maintained, discontinued or reduced dose of hydroxychloroquine during a prospective study of ophthalmological screening for retinopathy (PERFOCTAPS Stu	11
Prevalence of systemic lupus erythematosus-related symptoms assessed by using the Connective Tissue Disease Screening Questionnaire in a large population-based cohort	11
Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus	11
Immune complex–driven neutrophil activation and BAFF release: a link to B cell responses in SLE	11
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine	11
Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density	11
Canadian workplace experiences of systemic lupus erythematosus (SLE)	10
Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus	10
Infertility in systemic lupus erythematosus: what rheumatologists need to know in a new age of assisted reproductive technology	10
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis	10
Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy—a tertiary centre experience in an Appalachian state	10
Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study	10
MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lu	10
Molecular signatures of intrarenal complement receptorsC3AR1andC5AR1correlate with renal outcome in human lupus nephritis	10
Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity	10
Towards an understanding of the biopsychosocial determinants of CVD in SLE: a scoping review	10

Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial	10
CD4⁺T-cell cooperation promoted pathogenic function of activated naïve B cells of patients with SLE	9
Intermuscular adipose tissue in patients with systemic lupus erythematosus	9
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus	9
Circulating extracellular vesicles in Systemic Lupus Erythematosus: physicochemical properties and phenotype	9
State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus	9
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?	9
Potential involvement of circulating exosomal miRNA-146a in disease activity andTRAF6gene expression in juvenile proliferative lupus nephritis	9
Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis	9
Development and validation of a risk scoring system to identify patients with lupus nephritis in electronic health record data	9
Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease	9
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study	9
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132	9
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory	9
Abnormally high expression of D1-like dopamine receptors on lupus CD4⁺T cells promotes Tfh cell differentiation	9
Cross-sectional study of the effects of self-efficacy on fatigue and pain interference in black women with systemic lupus erythematosus: the role of depression, age and education	8
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort	8
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica	8
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit	8
Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review	8
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE	8
SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in systemic lupus erythematosus	8
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study	7
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials	7
Black patients with cutaneous lupus are associated with positive family history of cutaneous lupus and systemic lupus	7
Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies	7
Higher mortality risk from gynaecological neoplasms and non-Hodgkin’s lymphoma in patients with systemic lupus erythematosus: an observational study from the Spanish National Registry	7
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort	7
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance	7
Systemic Lupus Erythematosus Risk Probability Index: ready for routine use? Results from a Chinese cohort	7
Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data	7
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response	7
Development of a predictive model for systemic lupus erythematosus incidence risk based on environmental exposure factors	7
Smoking associates with distinct clinical phenotypes in patients with systemic lupus erythematosus: a nationwide Danish cross-sectional study	7
Characteristics of cardiovascular autonomic dysfunction and association with quality of life in patients with systemic lupus erythematosus	7
Joint surgery rates in lupus: a long-term cohort study	6
Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus	6
Characteristics and clinical outcomes of patients with systemic lupus erythematosus initiating anifrolumab in a real-world setting in Spain (AZAHAR study): an observational study protocol	6
Targeted multiomics in childhood-onset SLE reveal distinct biological phenotypes associated with disease activity: results from an explorative study	6
Microvascular C5b-9 deposition in non-lesional skin in patients with SLE and its correlation with active lupus nephritis: a prospective observational study	6
Personalised therapy during preconception and gestation in SLE: usefulness of 6-mercaptopurine metabolite levelswith azathioprine	6
Association of race and ethnicity with mortality in adults with SLE: a systematic literature review and meta-analysis	6
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE	6
Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study	6
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus	6
Vaginal microbiota affects urinary tract infection risk in women with systemic lupus erythematosus: a pilot cross-sectional study from Thailand	6
Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report	6
Clinical trial outcomes for SLE: what we have and what we need	6
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort	6
Effect of hydroxychloroquine on pregnancy outcome in patients with SLE: a systematic review and meta-analysis	5
Are patients with systemic lupus erythematosus at increased risk for COVID-19? A bi-directional Mendelian randomisation study	5
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus	5
Prediction of mortality risk in critically ill patients with systemic lupus erythematosus: a machine learning approach using the MIMIC-IV database	5
Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state f(unctional) MRI study	5
Central nervous system infections in patients with systemic lupus erythematosus: a systematic review and meta-analysis	5
Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case–control study	5
Prevalence and correlates of restricted community mobility in a population-based cohort of adults with systemic lupus erythematosus	5
Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway	5
Ancestry,ACKR1and leucopenia in patients with systemic lupus erythematosus	5
Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome	5
Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA	5
Combining C reactive protein and serum albumin to predict 90-day mortality in systemic lupus erythematosus with serious community-acquired infections	5
p16^Ink4a, a marker of cellular senescence, is associated with renal disease in the B6.NZMSle1/Sle2/Sle3mouse model of lupus	5
Herpes zoster in SLE: prevalence, incidence and risk factors	5
Correction: Differences in reproductive health discussions in an urban hispanic population with SLE: lessons from the field	5
Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model	5
Investigations intoSCAMP5,a candidate lupus risk gene expressed in plasmacytoid dendritic cells	5
Use of a screening questionnaire for systemic lupus erythematosus among pregnant women in a Mexican population	5
Improving routine mental health screening for depression and anxiety in a paediatric lupus clinic: a quality improvement initiative for enhanced mental healthcare	4
“There’s so much to be done”: a qualitative study to elucidate research priorities in childhood-onset systemic lupus erythematosus	4
Real-world effectiveness of belimumab in patients with lupus in China: RELIABLE observational cohort study protocol	4
Non-criteria antiphospholipid antibody profiles and thrombotic outcomes in a cohort of patients with systemic lupus erythematosus	4
Utility of skin biopsy in patients with systemic lupus erythematosus	4
Myocardial Performance Index to assess cardiac function in autoimmune connective tissue disease: a systematic review and meta-analysis	4
5-Hydroxymethylcytosine in circulating cell-free DNA as a potential diagnostic biomarker for SLE	4
Systemic blockade of proBDNF inhibited the expansion and altered the transcriptomic expression in CD3⁺B220⁺cells in MRL/lpr lupus mice	4
Methyl-donor supplementation in women with systemic lupus erythematosus with different nutritional status: the protocol for a randomised, double-blind, placebo-controlled trial	4
Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis	4
Large overlap in neutrophil transcriptome between lupus and COVID-19 with limited lupus-specific gene expression	4
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks	4

Novel potential lncRNA biomarker in B cells indicates essential pathogenic pathway activation in patients with SLE	4
Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021	4
Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards	4
Favourable humoral but reduced cellular immune response to COVID-19 mRNA BNT162b2 vaccine in patients with childhood-onset systemic lupus erythematosus	4
Investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of young people with childhood-onset systemic lupus erythematosus	4
Consequences of medication unavailability on patient anxiety: the example of the 2020 hydroxychloroquine availability crisis for patients with SLE – 18 months later	4
Impaired regulatory function of granzyme B-producing B cells against T cell inflammatory responses in lupus mice	4
Association of genetic variation on X chromosome with systemic lupus erythematosus in both Thai and Chinese populations	4
Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis	4
Topological structural characteristics in patients with systemic lupus erythematosus with and without neuropsychiatric symptoms	4
Efficacy of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis: a single-centre historical control study	4
Clinical and histopathological features of myositis in systemic lupus erythematosus	3
Frequency of sarcopenia in Turkish women with systemic lupus erythematosus	3
Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria	3
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE	3
Clinical associations of cognitive dysfunction in systemic lupus erythematosus	3
Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity	3
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial	3
Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE	3
EXamining the feasibility of exerCisE to manage symptoms of Lupus (EXCEL): a protocol for a randomised controlled pilot study	3
Hydroxychloroquine in patients with systemic lupus erythematosus: how much is enough?	3
Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial	3
Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study	3
A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus	3
ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies	3
Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations	3
Frailty and emergency department utilisation in adults with systemic lupus erythematosus ≤65 years of age: an administrative claims data analysis of Medicaid beneficiaries	3
Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus	3
Intermediate monocytes in blood correlate with subclinical vascular changes in lupus nephritis	3
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus	3
What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts	3
Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004–2015	3
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network	3
Development and evaluation of a Register-Based Organ Damage Index in systemic lupus erythematosus: a nationwide, population-based study from Sweden	3